Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

Healthcare Cannabis
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Medipharm Labs Corp > Key Point here from DEA because LABS has already been
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(603)
•••
Post by subaru1ion Jan 28, 2024 1:17pm
96 Views
Post# 35849324

Key Point here from DEA because LABS has already been

Key Point here from DEA because LABS has already been involved with the DEA to export clinical trial materials for the NIH.


DEA Calls for Production of More Cannabis Compounds and Psilocybin – The Drug Enforcement Administration (DEA) has finalized significant increases in its 2024 production quotas for cannabis compounds and psychedelics. Responding to comments from registered manufacturers, the final order includes even higher production quotas for several Schedule I substances—including delta-9 THC and all other tetrahydrocannabinol–than initially proposed by the agency. According to the DEA, such increases were necessary to “allow for manufacturers to meet medical and scientific needs.”

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities